A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo
Sarah T. Diepstraten, Yexuan Deng, Margaret A. Potts, Amy J. Heidersbach, Christina Koenig, Kristel M. Dorighi, Lin Tai, Andrew J. Kueh, Lauren Whelan, Catherine W.T. Chang, Felix Brown, Gemma L. Kelly, Jean‐Philippe Fortin, Benjamin Haley, John E. La Marca, Marco J. Herold
This paper introduces Partita, a high-density CRISPRa platform for comprehensive gene activation studies, demonstrating its utility in identifying cancer dependencies and resistance pathways in vitro and in vivo.
Science Advances · Sep 18, 2026Peer-reviewedCancer Biology